Literature DB >> 18574655

Ocular distribution of intravenously administered micafungin in rabbits.

Takashi Suzuki1, Toshihiko Uno, Guangming Chen, Yuichi Ohashi.   

Abstract

The ocular distribution of micafungin (MCFG), which has antifungal activity against Candida and Aspergillus species, was followed after the systemic administration of MCFG in rabbits. After MCFG (10 mg/kg) plus fluconazole (FLCZ; 10 mg/kg) was administered intravenously, the rabbits were killed, and MCFG and FLCZ concentrations in retina-choroid, vitreous humor, and plasma were determined by high performance liquid chromatography or liquid chromatography/mass spectrometry. The mean concentrations of MCFG in the retina-choroid at 0.25, 0.75, 4, 8, and 24 h after administration were 20.18, 15.97, 13.19, 6.27, and 0.75 microg/g, respectively, and were comparable with the MCFG plasma concentrations. The MCFG concentrations in retina-choroid and plasma exceeded the minimal antifungal inhibitory concentrations for endophthalmitis, although MCFG was not detected in the vitreous humor. These results suggest that the intravenous administration of MCFG is an effective treatment for endogenous fungal endophthalmitis when the causative fungus is localized in the retina and choroid.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18574655     DOI: 10.1007/s10156-008-0612-5

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  11 in total

Review 1.  Ocular drug delivery.

Authors:  Ripal Gaudana; Hari Krishna Ananthula; Ashwin Parenky; Ashim K Mitra
Journal:  AAPS J       Date:  2010-05-01       Impact factor: 4.009

2.  Multicenter prospective observational study of fungal keratitis in Japan: analyses of in vitro susceptibility tests for combinations of drugs.

Authors:  Keigo Kimura; Yoshitsugu Inoue; Seishi Asari; Atsuko Sunada; Yuichi Ohashi; Yoshikazu Shimomura; Chie Sotozono; Hiroshi Hatano; Masahiko Fukuda; Hiroshi Eguchi; Kaoru Araki-Sasaki; Takashi Suzuki; Saichi Hoshi; Toru Tobe; Takashi Yaguchi; Koichi Makimura
Journal:  Jpn J Ophthalmol       Date:  2022-03-29       Impact factor: 2.447

3.  Pros and Cons of Extrapolating Animal Data on Antifungal Pharmacodynamics to Humans.

Authors:  Scott W Mueller; Tyree H Kiser
Journal:  Curr Fungal Infect Rep       Date:  2011-03-26

4.  Intraocular penetration of intravenous micafungin in inflamed human eyes.

Authors:  Kiyofumi Mochizuki; Akira Sawada; Shinsuke Suemori; Hideaki Kawakami; Yoshiaki Niwa; Yuji Kondo; Kiyofumi Ohkusu; Noriaki Yamada; Shinji Ogura; Takashi Yaguchi; Kazuko Nishimura; Satoshi Kishino
Journal:  Antimicrob Agents Chemother       Date:  2013-05-20       Impact factor: 5.191

5.  Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David R Andes; Cornelius J Clancy; Kieren A Marr; Luis Ostrosky-Zeichner; Annette C Reboli; Mindy G Schuster; Jose A Vazquez; Thomas J Walsh; Theoklis E Zaoutis; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2015-12-16       Impact factor: 9.079

Review 6.  Tissue penetration of antifungal agents.

Authors:  Timothy Felton; Peter F Troke; William W Hope
Journal:  Clin Microbiol Rev       Date:  2014-01       Impact factor: 26.132

7.  The route of administration influences the therapeutic index of an anti-proNGF neutralizing mAb for experimental treatment of Diabetic Retinopathy.

Authors:  Pablo F Barcelona; Alba Galan; Hinyu Nedev; Yifan Jian; Marinko V Sarunic; H Uri Saragovi
Journal:  PLoS One       Date:  2018-06-21       Impact factor: 3.240

8.  Pharmacokinetics and pharmacodynamics of anidulafungin for experimental Candida endophthalmitis: insights into the utility of echinocandins for treatment of a potentially sight-threatening infection.

Authors:  J L Livermore; T W Felton; J Abbott; A Sharp; J Goodwin; L Gregson; P A Warn; S J Howard; W W Hope
Journal:  Antimicrob Agents Chemother       Date:  2012-10-31       Impact factor: 5.191

9.  Factors associated with the development of ocular candidiasis and ocular prognosis with echinocandin therapy for candidemia.

Authors:  Daiki Sakai; Wataru Matsumiya; Sentaro Kusuhara; Makoto Nakamura
Journal:  J Ophthalmic Inflamm Infect       Date:  2021-06-14

10.  Risk factors and outcomes of patients with ocular involvement of candidemia.

Authors:  Hyo-Ju Son; Min Jae Kim; Suhwan Lee; Sungim Choi; Kyung Hwa Jung; Jiwon Jung; Yong Pil Chong; Sung-Han Kim; Sang-Ho Choi; Yang Soo Kim; Jun Hee Woo; Joo Yong Lee; Sang-Oh Lee
Journal:  PLoS One       Date:  2019-09-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.